• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Member Resources

Pipelines in Oncology

December 14, 2006 - Novartis


Bill Sellers, MD - VP & Global Head, Oncology
Stephen Fawell, PhD - Executive Director Drug Discovery II

Presentation on:

  • Nilotinib-BCR-Abl inhibitor
  • RAD001-mTOR inhibitor
  • BEZ235- PI3K inhibitor
  • RAF265- RAF inhibitor
  • TKI 258- Multiple Kinase inhibitor
  • HCD122- Anti- CD4O Antibody
  • Overview Preclinical Projects/ Apoptosis

December 7, 2006 - Nerviano Medical Sciences (Italy)


Bernard. Laffranchi, MD Director of Clinical Research
Silvia Comis, MD - Senior Director of Clinical Development
Juergen Moll, PhD Director, Department of Cell Biology

Presentation on:

  • PHA-739358  - Aurora Kinase Inhibitor
  • PHA-767491  CDK Inhibitor

November 22, 2006 - Infinity Pharmaceuticals


Julian Adams, PhD President, Chief Scientific Officer
Jeffrey Tong, PhD - Vice President, Corporate Product Development 

Presentation on:

 IPI-609 Hedgehog Signalling Inhibitor

October 19, 2006 - Pfizer


Pierre Dodion, MD- Group Leader, US Medical Oncology, Pfizer Global Pharmaceuticals, NY
Louis J. Denis, MD - Clinical Research and Development, Oncology,
Pfizer Global Research and Development, New London, CT

Presentation on:

  • CP675.206 - a monoclonal antibody against CTLA4
  • PF3521,676 - a toll-like receptor agonist
  • Axitinib (AG13736)
  • Sutent http://www.sutent.com

September 21, 2006 - Genzyme


Johanne Kaplan, PhD - Vice President, Oncology Research
Jim Lillie, PhD - Vice President, Biochemistry
Frank Hsu, MD - Medical Director, Clinical Research

Presentation on:

  • Oncology Research at Genzyme
  • Small molecule discovery program at Genzyme
  • Generation of therapeutic antibodies
  • Campath research - http://www.campath.com/
  • Clinical programs: Campath; Clofarabine; anti-TGFb monoclonal antibody (GC1008) 

September 14, 2006 - Serono (now EMD Serono)


Paul Lammers, MSc - Chief Medical Officer, Serono, Inc. (Clinical and Current Pipeline)
Steve Arkinstall, D.Phil - Vice President, Research, Serono Research Institute, Inc. (Preclinical and Research Efforts)
Heather Hatfield - Director, Corporate and Scientific Communications
Ben Askew, PhD - Director of Chemistry
John Hermann, PhD - Director, Oncology Business Opportunities

Presentation on:

  • AS-703569  Aurora Kinase Inhibitor
  • AS-602868 IKK2 inhibitor


July 24, 2006 - GPC Biotech (Germany)


Martine George, MD, MSc SVP, Clinical Development
Hannes Loferer, PhD Senior Director, Research Project Management
Maureen Caliguri, PhD Principal ScientistLou Lamphere, PhD Director Pharmacology
Nicolai Kley, PhD Head of ResearchMarcel Rosencweig CMO and SVP Drug Development

Presentation on:

  • Satraplatin
  • ID09C3 Monoclonal Antibody
  • Cell-Cyle inhibitors


May 25, 2006 Array Biopharma


Mark Miglarese, PhD Assistant Director Translational Research
Mike Doyle, MD Director, Clinical Development and Regulatory Affairs

Presentation on:

  • ARRY-797 p38 alpha inhibitor
  • ARRY-886 MEK inhibitor
  • ARRY-520 KSP inhibitor


May 11, 2006 - Bristol-Myers Squibb


Renzo Canetta, MD - VP Oncology Global Research - Oncology and Immunology Susan Galbraith, PhD -  ED, Clinical Discovery - Oncology and Immunology Steven Averbuch,  MD - ED, Oncology Global Clinical Research Roberto Weinman, PhD - Director Discovery Biology
Edwin Clark, PhD - Director Oncology Biomarker Team

Presentation on:

  • Late Stage Development: Erbitux (http://www.erbitux.com) , Dasatinb , Ixabepilone and Vinflunine
  • Immunology: Ipilimumab and CD-137, Angiogenesis, VEGFR/FGFR
  • Early Development: Oral Taxane, Androgen Receptor Inhibitor, Multi-targeted Kinase Inhibitor
  • Preclinical Themes
  • Pharmacogenomics

April 20, 2006 - Millenium Pharmaceuticals


Michael Cooper,  MD - Head, Oncology Clinical Research, Senior Medical Director, Oncology Clinical Research
Dixie-Lee Esseltine, MD - Senior Medical Director, Oncology Clinical Research

Presentation on:

March 9, 2006 - AstraZeneca


Louise Grochow, MD - Senior Director, Clinical Research
Cathleen Wheeler, MD - Emerging Product Team Director
Jeff Hanke, PhD - Vice President Cancer Research

Presentation on:

  • AZD-6474 (Vandetanib, Zactima - VEGFR-2/KDR tyrosine kinase inhibitor )
  • AZD-2171 (VEGFR Kinase inhibitor)
  • AZD-1152 (Aurora Kinase Inhibitor)
  • AZD-0530 (Abl Kinase-, Src Kinase Inhibitor)
  • AZD-7762 (Check Point Inhibitor)
  • AZD-6244 (MEK-1, MEK-2 Inbibitor)
  • PARPi (Poly(ADP-ribose) Polymerase Inhibitors)

January 19, 2006 - Abraxis/American Bioscience


Michael J. Hawkins, MD - Chief Medical Officer
Neil Desai PhD - Vice President, R&D

Presentation on:

  • Update on Abraxane Clinical Trials:
    • Non-Small Cell Lung Cancer
    • Malignant Melanoma
    • Ph I- In Combination with Carboplatin
    • Correlation of Response with SPARC Expression in Head & Neck
    • http://www.abraxane.com/
  • Preclinical Development Program
  • Mechanistics and Applications of Nab-Technology
  • Pipeline Products:
    • nab-17AAG
    • nab-rapamycin
    • nab-thiocolchicine dimer
    • nab-docetaxel